Rheumatology Advance Access published online on September 14, 2004
Rheumatology, doi:10.1093/rheumatology/keh392
Rheumatology © British Society for Rheumatology 2004; all rights reserved
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Division of Rheumatology, Department of Medical and Surgical Sciences, University of Padua, Italy
* To whom correspondence should be addressed. E-mail: adoria{at}unipd.it.
Objective. To investigate the role of clinical, immunological and psychological variables in influencing the health-related quality of life (HRQOL) of Italian patients with systemic lupus erythematosus (SLE). Methods. The Medical Outcomes Study Short Form-36 was applied in a cohort of 126 SLE patients. At the time of HRQOL testing all patients underwent a clinical and laboratory evaluation, together with the measure of disease activity, severity and damage. In addition, a battery of psychological tests including the Hamilton Anxiety Scale (HAS) and the Hamilton Depression Rating scale (HAM-D) was applied. Results. The parameters which seemed to greatly influence the impairment of HRQOL were older age, arthralgia-arthritis and higher HAS scores as well as HAM-D. In multivariate analysis (adjusted for age), arthralgia-arthritis and a higher HAM-D score were associated with HRQOL impairment. No relationship between HRQOL and SLE activity, severity or damage were found. However, a relationship between HAS or HAM-D scores and damage or arthralgia-arthritis was noted. Conclusion. Anxiety, depression and joint pain seem to be the major determinants of HRQOL impairment in SLE patients. Damage seems to influence HRQOL mostly through depression.
Accepted August 4, 2004
Original Papers
Health-related quality of life in Italian patients with systemic lupus erythematosus. II. Role of clinical, immunological and psychological determinants
2 Department of Neuroscience, University of Padua, Italy
3 Department of Rheumatology, University of Ancona, Italy
Abstract 
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. APPENZELLER, A. E. CLARKE, P. PANOPALIS, L. JOSEPH, Y. ST. PIERRE, and T. LI The Relationship Between Renal Activity and Quality of Life in Systemic Lupus Erythematosus J Rheumatol, May 1, 2009; 36(5): 947 - 952. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dussan, L Magder, R. Brodsky, R. Jones, and M Petri High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures Lupus, December 1, 2008; 17(12): 1079 - 1085. [Abstract] [PDF]
|
|
|
|
|
|
A Doria and C Briani Lupus: improving long-term prognosis Lupus, March 1, 2008; 17(3): 166 - 170. [Abstract] [PDF]
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco Mycophenolate mofetil and systemic lupus erythematosus Lupus, November 1, 2006; 15(11_suppl): 44 - 54. [Abstract] [PDF]
|
|
|
|
|
|
K Mcelhone, J Abbott, and L -S Teh A review of health related quality of life in systemic lupus erythematosus Lupus, October 1, 2006; 15(10): 633 - 643. [Abstract] [PDF]
|
|
|
|
|
|
M Abu-Shakra, A Keren, I Livshitz, V Delbar, A Bolotin, S Sukenik, and Y Kanat-Maymon Sense of coherence and its impact on quality of life of patients with systemic lupus erythematosus Lupus, January 1, 2006; 15(1): 32 - 37. [Abstract] [PDF]
|
|